Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus
暂无分享,去创建一个
V. Werth | Wenting Wang | A. Gardet | A. Pellerin | D. Rabah | N. Franchimont | C. Mccarl | Rohan Diwanji | Douglas Donaldson
[1] P. Auluck,et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus , 2019, The Journal of clinical investigation.
[2] L. Rönnblom,et al. Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor , 2018, Arthritis Research & Therapy.
[3] R. Landewé,et al. Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort , 2018, Arthritis Research & Therapy.
[4] V. Werth,et al. Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. , 2017, The journal of investigative dermatology. Symposium proceedings.
[5] C. Huard,et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis , 2017, The British journal of dermatology.
[6] C. Ponticelli,et al. Hydroxychloroquine in systemic lupus erythematosus (SLE) , 2017, Expert opinion on drug safety.
[7] K. Kalunian,et al. Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus , 2017, Arthritis & rheumatology.
[8] S. de Ridder,et al. Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters , 2016, Arthritis Research & Therapy.
[9] L. Langman,et al. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis , 2016, Arthritis care & research.
[10] T. Gambichler,et al. Cutaneous characteristics and association with antinuclear antibodies in 402 patients with different subtypes of lupus erythematosus , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.
[11] D. Olive,et al. Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells , 2016, PloS one.
[12] M. Petri,et al. OP0187 Hydroxychloroquine Blood Levels in Sle: Clarifying Dosing Controversies and Improving Adherence , 2015 .
[13] A. Ranger,et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms , 2015, EMBO molecular medicine.
[14] M. Marmor,et al. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. , 2014, JAMA ophthalmology.
[15] N. Costedoat-Chalumeau,et al. Hydroxychloroquine: a multifaceted treatment in lupus. , 2014, Presse medicale.
[16] N. Seidah,et al. Processing of human toll-like receptor 7 by furin-like proprotein convertases is required for its accumulation and activity in endosomes. , 2013, Immunity.
[17] C. Coch,et al. A Human In Vitro Whole Blood Assay to Predict the Systemic Cytokine Response to Therapeutic Oligonucleotides Including siRNA , 2013, PloS one.
[18] W. White,et al. Pharmacogenomics and Translational Simulations to Bridge Indications for an Anti‐Interferon‐α Receptor Antibody , 2013, Clinical pharmacology and therapeutics.
[19] V. Werth,et al. Cutaneous lupus erythematosus: diagnosis and treatment. , 2013, Best practice & research. Clinical rheumatology.
[20] K. Kalunian,et al. Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study , 2013, Arthritis and rheumatism.
[21] L. Criswell,et al. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus , 2012, Arthritis Research & Therapy.
[22] A. Davidson,et al. Taming lupus—a new understanding of pathogenesis is leading to clinical advances , 2012, Nature Medicine.
[23] V. Werth,et al. The interferon‐regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score , 2012, The British journal of dermatology.
[24] D. Lipsker,et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. , 2012, Archives of dermatology.
[25] P. Brown,et al. Interferon and Biologic Signatures in Dermatomyositis Skin: Specificity and Heterogeneity across Diseases , 2012, PloS one.
[26] T. Tenhave,et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. , 2011, Archives of dermatology.
[27] S. Greenberg,et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway , 2011, Annals of the rheumatic diseases.
[28] U. Švajger,et al. Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines , 2011, The Journal of Immunology.
[29] Sarah E. Ewald,et al. Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase , 2011, The Journal of experimental medicine.
[30] D. Tomasini,et al. Plasmacytoid dendritic cells: an overview of their presence and distribution in different inflammatory skin diseases, with special emphasis on Jessner's lymphocytic infiltrate of the skin and cutaneous lupus erythematosus , 2010, Journal of cutaneous pathology.
[31] M. Marmor,et al. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus , 2010, Arthritis care & research.
[32] J. Kere,et al. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus , 2010, Experimental dermatology.
[33] S. Maschalidi,et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. , 2009, Immunity.
[34] L. Cerroni,et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. , 2009, Immunobiology.
[35] Marion Jurk,et al. Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses1 , 2008, The Journal of Immunology.
[36] June-Yong Lee,et al. Dysfunctional interferon-α production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus , 2008, Arthritis Research & Therapy.
[37] R. Küppers,et al. CD303 (BDCA‐2) signals in plasmacytoid dendritic cells via a BCR‐like signalosome involving Syk, Slp65 and PLCγ2 , 2007, European journal of immunology.
[38] T. Bieber,et al. The expression pattern of interferon‐inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets , 2007, The British journal of dermatology.
[39] L. Lanier,et al. BDCA2/FcɛRIγ Complex Signals through a Novel BCR-Like Pathway in Human Plasmacytoid Dendritic Cells , 2007, PLoS biology.
[40] P. Emery,et al. The validity of the inclusion of "lupus headache" in the Systemic Lupus Erythematosus Disease Activity Index. , 2007, Arthritis and rheumatism.
[41] J. Piette,et al. Hydroxychloroquine in systemic lupus erythematosus , 2007, The Lancet.
[42] T. Bieber,et al. CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. , 2007, Journal of the American Academy of Dermatology.
[43] P. Fitzgerald-Bocarsly,et al. Receptor Cross-Linking on Human Plasmacytoid Dendritic Cells Leads to the Regulation of IFN-α Production1 , 2006, The Journal of Immunology.
[44] D. Furst,et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.
[45] J. Berlin,et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. , 2005, The Journal of investigative dermatology.
[46] A. Zlotnik,et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus. , 2005, Arthritis and rheumatism.
[47] M. Dall'era,et al. Type I interferon correlates with serological and clinical manifestations of SLE , 2005, Annals of the rheumatic diseases.
[48] M. Tomai,et al. Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, The Journal of Immunology.
[49] D. Golenbock,et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. , 2005, The Journal of clinical investigation.
[50] D. Gladman,et al. Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.
[51] S. Miltenyi,et al. BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood , 2000, The Journal of Immunology.
[52] G. Sturfelt,et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies , 2000, Lupus.
[53] N. Kadowaki,et al. The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.
[54] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[55] U. Mansmann,et al. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. , 1997, Acta dermato-venereologica.
[56] D. Crosby,et al. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. , 1994, The Journal of rheumatology.
[57] R. Day,et al. Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis. , 1994, British journal of rheumatology.
[58] L. Golitz,et al. Clinical, histologic, and immunofluorescent distinctions between subacute cutaneous lupus erythematosus and discoid lupus erythematosus. , 1992, The Journal of investigative dermatology.
[59] V. Werth,et al. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study , 2018, Journal of the American Academy of Dermatology.
[60] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[61] M. Dew,et al. A Prospective Analysis , 2015 .
[62] P A Dekker-de Kiefte,et al. Diagnosis and Treatment , 2020, Diabetes.
[63] Joan Abbott-chapman,et al. Longitudinal Cohort Analysis , 1992 .